On March 11, 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a pandemic. Along with the wider scientific community, we are committed to doing everything we can at Cube Labs to address this rapidly evolving, global health crisis.
DTech and Adamas Biotech, both Cube Labs companies, have together developed a prophylactic technology to combat COVID-19, soon to enter clinical trials.
bioCD19TM comprises a proprietary biogel-bioactive catechin mixture designed to be safely administered to the upper respiratory tract to prevent virus particles from infecting host cells. The components of the formulation have been tested for toxicity and safety.
Clinical studies will begin soon. For more information, Contact Us.